Skip to Main Content

Paper Details

Mesothelin is a novel cell surface disease marker and potential therapeutic target in acute myeloid leukemia.
Blood Adv
18
2021
AML, AML-restricted genes, DGN462, KMT2A, MSLN, MSLN transcript, MSLN+, MSLN+ AML, MSLN+ leukemia cell lines, Mesothelin, acute myeloid leukemia, anetumab ravtansine, anti-MSLN, children, core-binding factor fusions, extramedullary disease, inv(, leukemia, leukemic blasts, normal, patient, patients, solid tumors, transcriptomes
Author NameAffiliation
Rhonda E RiesFred Hutchinson Cancer Research Center
Rhonda E RiesFred Hutchinson Cancer Research Center
Todd A AlonzoUniversity of Southern California Keck School of Medicine
Todd A Alonzo
Todd A AlonzoUniversity of Southern California Keck School of Medicine
Todd A Alonzo
Timothy J TricheVan Andel Institute
Timothy J TricheVan Andel Institute
Steven M KornblauThe University of Texas MD Anderson Cancer Research Center
Edward A KolbNemours/Alfred I. Dupont Hospital for Children
Soheil MeshinchiFred Hutchinson Cancer Research Center
Soheil MeshinchiFred Hutchinson Cancer Research Center
  • 1 - 12

Datasets

Release 1.2